Has the prognosis of septic patients improved over time

作者: P. Pickkers , Q.L.M. Habes

DOI:

关键词:

摘要: Over the last decades multiple clinical trials searching for an effective pharmacological treatment sepsis have failed to identify ‘a magic bullet’ that significantly improves outcome in patients suffering from sepsis. Moreover, several interventions appeared exert beneficial effects were not confirmed be randomised controlled trials. 2-4 It seems suffers more negative than any other disease. Yet, despite absence of a single treatment, March this year Kaukonen and co-workers published retrospective, observational study which they reported overall decrease mortality Australia New Zealand. 5 one decade, 171 participating ICUs, 100,000 included. In detail, absolute severe decreased 35.0% 2000 18.4% 2012. This represents 16.7%, with gradual decline 1.3% annually. is compelling epidemiological on first sight may conclude prognosis has improved considerably. However, caution needed interpretation studies. Several possible explanations observed need addressed. Similar discussions related population-wide screening cancer, increased awareness also lead earlier diagnosis patients. The subsequent less advanced disease suggest better survival time (and thus lower mortality), while truly case. Indeed, Kaukonen’s study, over fewer suffered concomitant respiratory failure (60 vs 37%) or renal (30 25%), important covariates are mostly present at ICU admission known influence outcome. Also, according quartiles APACHE III scores as measure their severity illness, sick admitted incidence urosepsis (with

参考文章(9)
Protocol-based care for early septic shock. The New England Journal of Medicine. ,vol. 371, pp. 386- ,(2014) , 10.1056/NEJMC1406745
Catherine Plowright, World Sepsis Day Nursing in Critical Care. ,vol. 18, pp. 214- 214 ,(2013) , 10.1111/NICC.12034_4
Kirsi-Maija Kaukonen, Michael Bailey, Satoshi Suzuki, David Pilcher, Rinaldo Bellomo, Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012 JAMA. ,vol. 311, pp. 1308- 1316 ,(2014) , 10.1001/JAMA.2014.2637
P. Pickkers, M. Tromp, D. H. T. Tjan, G. J. D. Goekoop, C. M. Wallenborg, A. R. H. Van Zanten, S. E. M. Gielen-Wijffels, H. S. Biemond-Moeniralam, M. Van Den Boogaard, The effects of implementation of the Surviving Sepsis Campaign in the Netherlands. Netherlands Journal of Medicine. ,vol. 69, pp. 292- 298 ,(2011)
, A Randomized Trial of Protocol-Based Care for Early Septic Shock The New England Journal of Medicine. ,vol. 370, pp. 1683- 1693 ,(2014) , 10.1056/NEJMOA1401602
V Marco Ranieri, B Taylor Thompson, Philip S Barie, Jean-François Dhainaut, Ivor S Douglas, Simon Finfer, Bengt Gårdlund, John C Marshall, Andrew Rhodes, Antonio Artigas, Didier Payen, Jyrki Tenhunen, Hussein R Al-Khalidi, Vivian Thompson, Jonathan Janes, William L Macias, Burkhard Vangerow, Mark D Williams, None, Drotrecogin alfa (activated) in adults with septic shock The New England Journal of Medicine. ,vol. 366, pp. 2055- 2064 ,(2012) , 10.1056/NEJMOA1202290
Charles L. Sprung, Djillali Annane, Didier Keh, Rui Moreno, Mervyn Singer, Klaus Freivogel, Yoram G. Weiss, Julie Benbenishty, Armin Kalenka, Helmuth Forst, Pierre-Francois Laterre, Konrad Reinhart, Brian H. Cuthbertson, Didier Payen, Josef Briegel, Hydrocortisone Therapy for Patients with Septic Shock The New England Journal of Medicine. ,vol. 358, pp. 111- 124 ,(2008) , 10.1056/NEJMOA071366
Intensive versus conventional glucose control in critically ill patients. The New England Journal of Medicine. ,vol. 360, pp. 1283- 1297 ,(2009) , 10.1056/NEJMOA0810625
Arthur RH van Zanten, Sylvia Brinkman, M Sesmu Arbous, Ameen Abu-Hanna, Mitchell M Levy, Nicolette F de Keizer, Netherlands Patient Safety Agency Sepsis Expert Group, Guideline Bundles Adherence and Mortality in Severe Sepsis and Septic Shock Critical Care Medicine. ,vol. 42, pp. 1890- 1898 ,(2014) , 10.1097/CCM.0000000000000297